This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Texas A&M University System, Texas Heart Institute, University of Houston System. Active years: 2013-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 1,330 
2 out of 35 
2 out of 619 
Years Active: 2013-2015
Title: Vladimir N Potaman: Innovator in Cardiac Progenitor Research
Introduction
Vladimir N Potaman is a notable inventor based in Houston, Texas. He has made significant contributions to the field of cardiac research, particularly in the generation of cardiac progenitor cells from fibroblasts. With a total of two patents to his name, Potaman's work is paving the way for advancements in regenerative medicine.
Latest Patents
Potaman's latest patents focus on methods for modulating cell differentiation capabilities using heterologous gene expression. His inventions, titled "ETS2 and MESP1 generate cardiac progenitors from fibroblasts," detail a method for inducing cardiac progenitor cells by delivering a reprogramming factor to the cells. This reprogramming factor includes ETS2 or a combination of ETS2 and Mesp1, showcasing Potaman's innovative approach to cellular reprogramming.
Career Highlights
Throughout his career, Potaman has worked with esteemed institutions such as the University of Houston System and the Texas Heart Institute. His research has contributed to a deeper understanding of cardiac biology and the potential for regenerative therapies.
Collaborations
Potaman has collaborated with notable colleagues, including Robert J Schwartz and Jose Francisco Islas. These partnerships have enhanced the scope and impact of his research in the field of cardiac progenitor cell development.
Conclusion
Vladimir N Potaman's work in cardiac progenitor research exemplifies the innovative spirit of modern science. His patents and collaborations reflect a commitment to advancing medical knowledge and therapeutic possibilities.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile